Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Evommune, Inc.NYSE: EVMN
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 475.6% from a year ago
Total assets stood at $322.46M at the end of Q1 FY2026, up 475.6% from a year earlier and up 43.3% from the prior quarter.
Context
- Total assets increased in 1 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +475.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 224.95M USD
- Year-over-year change
- +195.8%
- 2-year CAGR
- +65.4%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 224.95M | +195.8% |
| FY2024 | 2024-12-31 | 76.06M | -7.5% |
| FY2023 | 2023-12-31 | 82.25M | — |
Total Assets vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 total assets of $322.46M is the 4th highest of the 10 companies compared; the peer median is $288.22M.
- Its year-over-year change of +475.6% is the highest of 10, against a peer median of -4.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
FTREFortrea Holdings Inc. | Jun 2026 | $2.71B | -4.2% | -14.1% |
| Jun 2026 | $2.19B | +130.4% | +27.0% | |
| Sep 2026 | $1.18B | +196.1% | -18.9% | |
EVMNEvommune, Inc. | Mar 2026 | $322.46M | +475.6% | — |
| Mar 2026 | $293.65M | -4.1% | -10.6% | |
| Mar 2026 | $288.22M | -20.5% | +26.4% | |
CLYMClimb Bio, Inc. | Mar 2026 | $152.37M | -24.1% | +7.5% |
| Mar 2026 | $131.42M | +2.9% | -32.9% | |
| Mar 2026 | $129.37M | +0.4% | -16.1% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $105.96M | -44.6% | -0.5% |
| Peer median (excluding EVMN) | $288.22M | -4.1% | -10.6% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.